Bellerophon Therapeutics, Inc.
BLPHNASDAQHealthcare
$0.01
$-0.01(-36.84%)
Market Cap$146791
P/E Ratio—
52W High$0.1
52W Low$0.01
Bellerophon Therapeutics, Inc. (BLPH) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BLPH · earnings · updated Jun 9, 2026
Latest Earnings
Q4 FY2023Report Date: Nov 14, 2023EPS Actual
-$0.16
Est. -$0.44 · +63.6%
Revenue
—
Fiscal Period
Q4 FY2023
FY ends December
Report Date
Nov 14, 2023
After Market Close
▲ Beat EPS✓ 3-Quarter EPS Beat Streak
BLPH reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2024 | Sep 23, 2024 | — | — | — | — | — | — |
| ◌ Q2 FY2024 | Jun 6, 2024 | -$0.42 | — | — | — | — | — |
| ◌ Q1 FY2024 | Mar 1, 2024 | -$0.33 | — | — | — | — | — |
| ▲ Q4 FY2023 | Nov 14, 2023 | -$0.44 | -$0.16 | +63.6% | — | — | — |
| — Q3 FY2023 | Aug 14, 2023 | -$0.42 | -$0.42 | +0.0% | — | — | — |
| ▲ Q2 FY2023 | May 15, 2023 | -$0.48 | $0.15 | +131.3% | $0.01B | — | — |
| ▼ Q1 FY2023 | Mar 31, 2023 | -$0.48 | -$0.53 | -10.4% | — | — | — |
| ▲ Q4 FY2022 | Nov 14, 2022 | -$0.59 | -$0.53 | +10.2% | — | — | — |
Q3 FY2024
Sep 23, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2024
Jun 6, 2024
EPS Actual
—
EPS Est.
-$0.42
EPS Surpr.
—
Revenue
—
Q1 FY2024
Mar 1, 2024
EPS Actual
—
EPS Est.
-$0.33
EPS Surpr.
—
Revenue
—
Q4 FY2023
Nov 14, 2023Beat
EPS Actual
-$0.16
EPS Est.
-$0.44
EPS Surpr.
+63.6%
Revenue
—
Q3 FY2023
Aug 14, 2023
EPS Actual
-$0.42
EPS Est.
-$0.42
EPS Surpr.
+0.0%
Revenue
—
Q2 FY2023
May 15, 2023Beat
EPS Actual
$0.15
EPS Est.
-$0.48
EPS Surpr.
+131.3%
Revenue
$0.01B
Q1 FY2023
Mar 31, 2023Miss
EPS Actual
-$0.53
EPS Est.
-$0.48
EPS Surpr.
-10.4%
Revenue
—
Q4 FY2022
Nov 14, 2022Beat
EPS Actual
-$0.53
EPS Est.
-$0.59
EPS Surpr.
+10.2%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2029 | $-0.33 | $-0.33 | $-0.33 | 1 |
| Q1 FY2029 | $-0.33 | $-0.33 | $-0.33 | 1 |
| Q4 FY2028 | $-0.43 | $-0.43 | $-0.43 | 1 |
| Q3 FY2028 | $-0.49 | $-0.49 | $-0.49 | 1 |
| Q2 FY2028 | $-0.48 | $-0.48 | $-0.48 | 1 |
| Q1 FY2028 | $-0.58 | $-0.58 | $-0.58 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2029 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q4 FY2023 | Nov 14, 2023 | +63.6% | $0.03 | $0.03 | -5.23% |
| ▲ Q3 FY2023 | Aug 14, 2023 | +0.0% | $0.43 | $0.40 | -6.98% |
| ▲ Q2 FY2023 | May 15, 2023 | +131.3% | $8.77 | $8.71 | -0.68% |
| ▼ Q1 FY2023 | Mar 31, 2023 | -10.4% | $7.46 | $7.89 | +5.76% |
| ▲ Q4 FY2022 | Nov 14, 2022 | +10.2% | $1.10 | $1.12 | +1.82% |
| ▲ Q3 FY2022 | Aug 15, 2022 | +29.5% | $1.42 | $1.40 | -1.41% |
| ▼ Q2 FY2022 | May 11, 2022 | -7.3% | $0.90 | $0.85 | -5.50% |
| ▲ Q1 FY2022 | Mar 31, 2022 | +25.0% | $2.34 | $2.36 | +0.85% |
Q4 FY2023-5.23%
Report Date
Nov 14, 2023
EPS Beat/Miss
+63.6%
Price Before
$0.03
Price After
$0.03
Q3 FY2023-6.98%
Report Date
Aug 14, 2023
EPS Beat/Miss
+0.0%
Price Before
$0.43
Price After
$0.40
Q2 FY2023-0.68%
Report Date
May 15, 2023
EPS Beat/Miss
+131.3%
Price Before
$8.77
Price After
$8.71
Q1 FY2023+5.76%
Report Date
Mar 31, 2023
EPS Beat/Miss
-10.4%
Price Before
$7.46
Price After
$7.89
Q4 FY2022+1.82%
Report Date
Nov 14, 2022
EPS Beat/Miss
+10.2%
Price Before
$1.10
Price After
$1.12
Q3 FY2022-1.41%
Report Date
Aug 15, 2022
EPS Beat/Miss
+29.5%
Price Before
$1.42
Price After
$1.40
Q2 FY2022-5.50%
Report Date
May 11, 2022
EPS Beat/Miss
-7.3%
Price Before
$0.90
Price After
$0.85
Q1 FY2022+0.85%
Report Date
Mar 31, 2022
EPS Beat/Miss
+25.0%
Price Before
$2.34
Price After
$2.36
Avg Beat Reaction-1.94%
Avg Miss Reaction+0.13%
Beat Rate6 / 8 quarters
Largest Move-6.98% (Q3 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BLPH ends December
Bellerophon Therapeutics, Inc. (BLPH) most recently reported earnings on November 14, 2023 for Q4 FY2023, posting EPS of $-0.16 — beating the analyst consensus of $-0.44 by +63.6%. BLPH has beaten EPS estimates for 3 consecutive quarters. The next BLPH earnings date is expected around September 1, 2026.
Each quarter, investors track BLPH earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BLPH revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BLPH's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BLPH earnings · 5 questionsBellerophon Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. BLPH typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BLPH historically reports after market close (AMC).
BLPH earnings datewhen is BLPH earningsBLPH next earnings datewhen does BLPH report earningsBLPH earnings calendar
▸ Source: FMP · Bellerophon Therapeutics, Inc. SEC filings · US GAAP · Bellerophon Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026